anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells

We here demonstrate that the anti-diabetic drug metformin interacts synergistically with the anti-HER2 monoclonal antibody trastuzumab (Tzb; Herceptin™) to eliminate stem/progenitor cell populations in HER2-gene-amplified breast carcinoma cells. When using the mammosphere culture technique, graded c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2011-04, Vol.126 (2), p.355-364
Hauptverfasser:	Vazquez-Martin, Alejandro, Oliveras-Ferraros, Cristina, Barco, Sonia Del, Martin-Castillo, Begoña, Menendez, Javier A
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Antimitotic agents Antineoplastic agents Antineoplastic Agents - pharmacology Biological and medical sciences Biological products Biomarkers, Tumor - metabolism Breast cancer Breast carcinoma Breast Neoplasms - pathology Cancer Cancer research Cancer therapies CD24 Antigen - metabolism Cell culture Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects Diabetes Diabetes therapy Drug Resistance, Neoplasm Drug Synergism Drugs ErbB-2 protein Female Flow cytometry Genetic aspects Gynecology. Andrology. Obstetrics HER2 Humans Hyaluronan Receptors - metabolism Mammary gland diseases Medical sciences Medicine Medicine & Public Health Metformin Metformin - pharmacology Models, Biological Monoclonal antibodies Neoplastic Stem Cells - drug effects Oncology Phenotype Preclinical Study Receptor, ErbB-2 - metabolism Stem cells Toy industry Trastuzumab Tumor-initiating cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!